Trial results

A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus

NCT06235086 on ClinicalTrials.gov · last registry update 2026-04-03

Finished 3 February 2026, after enrolling 632 people. Primary outcome, as filed: Changes in glycosylated hemoglobin (HbA1c) from baseline at 28 weeks of treatment. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P3

Drug

dulaglutide

Trulicity

Sponsor

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Sponsor type

Industry

Enrollment

632

Started

2024-04-08

Primary completion

2026-02-03 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Changes in glycosylated hemoglobin (HbA1c) from baseline at 28 weeks of treatment

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.